Navigation Links
Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
Date:3/27/2008

- Emerging Data Shows Encouraging Response in CF Patients

- Results Validate Investment in Venture Philanthropy Business Model

BETHESDA, Md., March 27 /PRNewswire/ -- The Cystic Fibrosis Foundation announced today that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.

Patients who took the drug for 14 days showed significant improvements in several key indicators of cystic fibrosis, including lung function, nasal potential difference measurements and sweat chloride levels. The findings suggest that VX-770 improves function of what is known as the faulty CFTR protein. This early data is promising and could have important implications for studies of other drugs in development.

This is the first time that any potential therapy has improved the abnormal sweat chloride (salt) levels in a person with CF. Excessive sweat chloride is a key clinical indicator of cystic fibrosis. The "sweat test" is the traditional diagnostic test for CF.

"These early results are an extraordinary endorsement of our hypothesis- that small molecules can correct the basic defect and affect the clinical indicators of cystic fibrosis," said Robert J. Beall, Ph.D., president and CEO of the Foundation. "The emerging data for VX-770 represents the most exciting results we've seen from a Phase 2 trial and increase our confidence that we're on the right track."

The compound VX-770 resulted from a collaboration between the Foundation and Vertex. In 1998, the Foundation approached Aurora Biosciences (acquired by Vertex in 2001) and made an initial investment to use cutting-edge technology- known as high throughput screening-to find compounds to attack the core defect in CF. Since that time, the Foundation has invested $79 million in the project, and the t
'/>"/>

SOURCE Cystic Fibrosis Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Promising Cystic Fibrosis Compound on Track for Development
2. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
3. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
4. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
5. Kevin McHale Instrumental in Forming the Help Me Hear Foundation
6. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
7. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
8. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
9. The Oral Cancer Foundation Urges HPV Vaccination for Males
10. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
11. Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015 /CNW/ - Covalon Technologies Ltd. ... medical technologies company, is delighted to announce its ... 31, 2015, which includes revenue for three months ... of $264,340. Revenue from advanced wound care product sales ... 2015 increased 24% to $1,742,672 compared to $1,400,065 ...
(Date:5/29/2015)... 29, 2015  Epic Sciences announced today that the ... metastatic castrate resistant prostate cancer patients, at the ... Clinical Oncology. This application expands the investigational utility ... platform to characterize circulating tumor cell (CTC) ... patients have heterogeneous clonal CTC populations harboring separate ...
(Date:5/29/2015)... NEW YORK , May 29, 2015  World-renowned prostate ... evaluates new findings on the benefit of MR/Ultrasound Fusion-Guided ... "Our Prostate Cancer Center at Lenox ... MR/Ultrasound Fusion Biopsy System in New York City ... high and low risk prostate cancers. The use of an ...
Breaking Medicine Technology:Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2
... 2011 Savvy executives in pharmaceutical commercial functions ... in today,s volatile healthcare environment. Quantitative and qualitative ... for increased resources, justify costs, or signal necessary ... presidents, directors, and managers tasked with right-sizing investment ...
... Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the ... European Medicines Agency (EMA) has granted orphan designation for ... B. Orphan designation in the European Union provides several ... launch and access to the central authorization procedure. ...
Cached Medicine Technology:Pharmaceutical Investment & Cost Benchmarks Accessed Quickly Through Best Practices, LLC's New Database Search Function 2Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy 2
(Date:5/29/2015)... 29, 2015 Wimbledon Health Partners, the ... (EKG), echocardiogram and NCV testing, is proud to ... for EKG interpretation of athletes. , ... death during athletic activity. New findings presented in February ... to improve cardiac safety in athletes. Physiologic adaptations in ...
(Date:5/29/2015)... 29, 2015 Thursday, May 21st was the ... from all walks of life came together to raise money ... Day is a campaign dedicated to raising money for children ... and making people laugh, the people at Hands-On Seminars decided ... Here they provided food, fun and laughter to their ...
(Date:5/29/2015)... 2015 Belviq for weight loss ... prescription diet medication. In 2012, the FDA approved ... have a BMI >30. It is also approved ... one additional weight-related health condition such as high blood ... main function for weight loss focuses on the brain’s ...
(Date:5/28/2015)... External Counterpulsation (EECP/ECP) has been used ... United States. There are a growing number of people ... symptoms of angina and these patients are often times ... surgery. , “No option” patients are a sizable cohort ... that is considered unacceptable for heart stent or bypass. ...
(Date:5/28/2015)... May 28, 2015 AMVETS National Executive ... the Commission on Care established by Congress to examine ... veterans. , Appointed to the commission by Mitch McConnell, ... be one of only 15 voting members on the ... and Accountability Act of 2014. The goal of the ...
Breaking Medicine News(10 mins):Health News:Wimbledon Health Partners Incorporates Updated ‘Seattle Criteria’ for EKG Interpretation of Athletes 2Health News:Wimbledon Health Partners Incorporates Updated ‘Seattle Criteria’ for EKG Interpretation of Athletes 3Health News:Groups, such as Hands-On Physical Therapy, Across the Country, Host Their Own Events and Make the Inaugural Red Nose Day a Huge Success 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 3Health News:External Counterpulsation (EECP/ECP) a New Heart Disease Therapy Helps People of Calgary with Unstable Angina 2Health News:AMVETS Executive Director Stewart Hickey Appointed to Congressional Commission on Care 2
... , TUESDAY, Feb. 22 (HealthDay News) -- People with chronic ... to develop shingles, according to a new study. Shingles ... a painful rash with lesions. Though it was already ... increased risk for the condition, the researchers of the current ...
... A U.S. law protects drug makers from lawsuits filed for ... ruled Tuesday. The court, in a six-to-two vote, decided ... problems were caused by a diphtheria, tetanus and pertussis vaccine ... sued the vaccine maker, Wyeth, which was acquired by Pfizer ...
... The American Society for Gastrointestinal Endoscopy (ASGE) has recognized ... dedicated to promoting quality in endoscopy, in all settings ... ASGE Endoscopy Unit Recognition Program honors endoscopy units that ... reprocessing and CDC infection control guidelines. To date, 307 ...
... By Jenifer Goodwin HealthDay Reporter , TUESDAY, ... brain,s electrical activity, researchers say they,ve been able to assess ... age. Researchers hooked up 79 babies aged 6 to ... activity in the brain. Forty-six of the infants had an ...
... Calif., Feb. 22, 2011 Getting more exercise, spending ... that can be as effective as drugs or counseling ... and anxiety, according to a UC Irvine study. ... & human behavior, philosophy and anthropology, as well as ...
... TUESDAY, Feb. 22 (HealthDay News) -- People with inflammatory ... potentially deadly blood clot (venous thromboembolism) in the legs ... a new study finds. Inflammatory bowel disease includes ... cause abdominal pain, vomiting, diarrhea, weight loss and other ...
Cached Medicine News:Health News:Supreme Court Rejects Vaccine-Safety Lawsuit 2Health News:ASGE recognizes 35 endoscopy units for quality and safety as part of its Endoscopy Unit Recognition Program 2Health News:ASGE recognizes 35 endoscopy units for quality and safety as part of its Endoscopy Unit Recognition Program 3Health News:ASGE recognizes 35 endoscopy units for quality and safety as part of its Endoscopy Unit Recognition Program 4Health News:Brain's Electrical Activity May Help Spot Infants at High Risk for Autism 2Health News:Brain's Electrical Activity May Help Spot Infants at High Risk for Autism 3Health News:Therapeutic lifestyle changes as useful as drugs in improving mental health 2Health News:People With Bowel Disease at Higher Risk of Blood Clot in Lungs, Legs 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: